Status:
UNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence
Lead Sponsor:
Mansoura University
Conditions:
Wilms Tumor
Relapse
Eligibility:
All Genders
Up to 18 years
Phase:
NA
Brief Summary
Wilms' tumour staging and grading are used to give an idea about the prognosis. Advanced staging, diffuse anaplasia, predominant blastemal elements and lymph node invasion are indicators of poor progn...
Detailed Description
P53 is a tumour suppressor gene, and its mutation is identified in various types of human cancer. P53 protein accumulation in certain tumours is associated with tumour aggressiveness. The role of P53 ...
Eligibility Criteria
Inclusion
- All children presented with Wilms' tumour at the Urology and Nephrology Center, Mansoura University, Mansoura, Egypt from 2000 to 2014.
Exclusion
- Preoperative chemotherapy (due to areas of necrosis and haemorrhage hindering immunohistochemical staining).
- Patients with incomplete follow-up data.
Key Trial Info
Start Date :
February 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04758455
Start Date
February 14 2021
End Date
April 1 2021
Last Update
February 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura Urology and Nephrology Center. Faculty of Medicine, Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt, 35516